Gilead Sciences (GILD) Reports Q4 Earnings: $1.86 EPS, Surpasses Analyst Estimates

Gilead Sciences Inc. (GILD) reported fourth-quarter net income of $2.18 billion, or $1.86 per share on an adjusted basis, topping Zacks Investment Research’s average analyst estimate of $1.83. Revenue reached $7.93 billion, exceeding the $7.57 billion median forecast. The HIV and hepatitis C drugmaker also guided to full-year earnings of $8.45 to $8.85 per share.